This website is designed to provide information about the ICON8 Trials Programme encompassing ICON8 and ICON8B for both patients and collaborators.
Please read the COVID-19 Correspondence document to get essential guidance during this unprecedented time. If you require further guidance, do not hesitate to get in contact with the trial.
Please note that due to COVID-19, randomisation into ICON8B closed as of 08th April 2020. Please read the ICON8B Recruitment closure communication to investigators and research staff or contact the trial team with any queries.
ICON8 is a randomised three-arm, three stage Gynaecologic Cancer InterGroup (GCIG) phase III trial designed to evaluate the safety and efficacy of dose-dense, dose-fractionated carboplatin-paclitaxel chemotherapy in the treatment of patients with ovarian cancer.
Learn about ICON8:
ICON8B is a randomised two-arm, Gynaecologic Cancer Intergroup (GCIG) phase III trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer.
The latest accrual figures for February 2018 have been released.
The total numbers recruited:
across all the regions.